Krystal Biotech Announces Third Quarter 2026 Financial and Operating Results
Globe Newswire•02/11/2026•07:00 ET
0
Key Highlights
- ➤VYJUVEK revenue $127.3 million, up 30% year over year
- ➤Krystal authorized a $400 million share repurchase program
- ➤KB113 lesions showed more than 80% clinical regression in Gorlin syndrome study
- ➤Cash and investments totaled $1.2 billion at quarter-end
- ➤FY 2026 non-GAAP R&D and SG&A guidance is $155.0-$165.0
Expert Statements
Krish S. Krishnan, Chairman and Chief Executive Officer of Krystal Biotech
“Continued growth in VYJUVEK revenue is supporting profitability and funding the advancement of our pipeline. Our financial strength allows us to invest fully in these programs and our global commercial expansion while returning capital to shareholders. The $400 million share repurchase program, under which we expect to repurchase shares opportunistically over the next two years, reflects our confidence in Krystal’s long-term growth prospects and our commitment to disciplined capital allocation.”
$127.3 million in 3Q VYJUVEK global revenue and $1.1 billion since launch
KB113 clinical data demonstrate regression in more than 80% of assessed basal cell carcinoma lesions in patients with Gorlin syndrome
Get started
Create a free account to read the full story.